L-arginine n-lauryl ester | 197447-35-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-arginine n-lauryl ester
• 英文别名: L-arginine lauril ester；Arginine dodecyl ester；dodecyl (2S)-2-amino-5-(diaminomethylideneamino)pentanoate
• CAS: 197447-35-1
• 化学式: C₁₈H₃₈N₄O₂
• 分子量: 342.525
• InChiKey: OJAOCVYPSWZSRT-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  L-精氨酸 、 十二烷醇 在 盐酸 作用下， 反应 0.25h， 生成 L-arginine n-lauryl ester
  参考文献：
  名称：

  An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery

  摘要：

  By inserting L-arginine lauril ester (AL) into nanostructure lipid carriers (NLCs) and then coating with bovine serum albumin (BSA), pH-sensitive membranolytic and lysosomolytic nanocarriers (BSA-AL-NLCs) were developed. Hemolysis assay demonstrated the pH-sensitive biomembrane disruptional capability of AL and BSA-AL-NLCs. BSA-AL-NLCs did not disrupt biomembrane at pH 7.4 even at high concentration, exhibited ideal feasibility as lysosomolytic drug delivery nanoparticles without cytotoxicity. Confocal Laser Scanning Microscope (CLSM) images confirmed the lysosomolytic capability of BSA-AL-NLCs after internalized into MCF-7 (human breast cancer cell) via endosome-lysosome path in vitro. Paclitaxel (PTX) loaded BSA-AL-NLCs displayed pH-dependent release in vitro. In MCF-7 viability test with MTT assays, both the blank NLCs did not exhibit cellular toxicity. Of particular interest, the in vitro cell experiments demonstrated that the anti-tumor effect of PTX-loaded BSA-AL-NLCs was preferable to BSA-NLCs, even comparable with PTX solution, which indicated that AL served to facilitate lysosomal escape of BSA-AL-NLCs so as to improve the anti-cancer effect. Biodistribution and anti-cancer activity in vivo confirmed the improved tumor targeting and anti-cancer efficacy of BSA-AL-NLCs. The study suggested that the simple and small molecule of AL may render more nanocarriers lysosomolytic capability with lower cytotoxicity, as well as improved therapeutic index of loaded active agents. (c) 2012 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ijpharm.2012.06.040

文献信息

• Sustainded-release composition including amorphous polymer
  申请人：University Technology Corporation

  公开号：US20020132007A1

  公开（公告）日：2002-09-19

  Provided is a sustained release composition for sustained release of a pharmaceutical substance. The composition includes a biocompatible polymer that is highly amorphous and a pharmaceutical substance in a hydrophobic ion complex with an amphiphilic material. Also provided a compressed antisolvent method for manufacturing the composition, various product forms incorporating the composition and various uses for the composition.

  提供了一种用于缓慢释放药物物质的缓慢释放组合物。该组合物包括一种高度非晶态的生物相容性聚合物和一种与一种两性物质形成疏水离子复合物的药物物质。还提供了一种压缩反溶剂法制造该组合物的方法，包括该组合物的各种产品形式以及该组合物的各种用途。
• Biocompatible cationic detergents and uses therefor
  申请人：University Technology Corporation

  公开号：US20020032166A1

  公开（公告）日：2002-03-14

  Provided is a method for preparing a true, homogeneous solution of a pharmaceutical substance dissolved in an organic solvent in which the pharmaceutical substance is not normally soluble. Solubilization is obtained by forming a hydrophobic ion pair complex involving the pharmaceutical substance and an amphiphilic material. The resulting organic solution may be further processed to prepare pharmaceutical powders. A biodegradable polymer may be co-dissolved with the pharmaceutical substance and the amphiphilic material and may be incorporated into a pharmaceutical powder. A preferred method for preparing pharmaceutical powders is to subject the organic solution to gas antisolvent precipitation using a supercritical gas antisolvent such as carbon dioxide. Also provided is a method for making hollow particles having a fiber-like shape which would provide enhanced retention time in the stomach if ingested by a human or animal host. Further provided are novel biocompatible cationic surfactants and uses therefor, including the delivery, in vitro and in vivo, of nucleic acids into cells to transform the cells.

  提供了一种制备药物物质在有机溶剂中真正均质溶解的方法，其中药物物质通常不溶于有机溶剂。通过形成涉及药物物质和两性分子材料的疏水离子对复合物来获得溶解度。所得到的有机溶液可以进一步处理以制备药物粉末。生物可降解聚合物可以与药物物质和两性分子材料共溶，并可以并入药物粉末中。制备药物粉末的首选方法是将有机溶液经过超临界气体反溶剂沉淀使用超临界气体反溶剂如二氧化碳。此外，提供了一种制备纤维状空心粒子的方法，如果被人类或动物宿主吞咽，将提供增强的胃滞留时间。还提供了新型生物相容阳离子表面活性剂及其用途，包括将核酸在体外和体内传递到细胞中以转化细胞。
• Sustained-release composition including amorphous polymer
  申请人：——

  公开号：US06613358B2

  公开（公告）日：2003-09-02

  Provided is a sustained release composition for sustained release of a pharmaceutical substance. The composition includes a biocompatible polymer that is highly amorphous and a pharmaceutical substance in a hydrophobic ion complex with an amphiphilic material. Also provided is a compressed antisolvent method for manufacturing the composition, various product forms incorporating the composition and various uses for the composition.

  提供了一种持续释放药物的持续释放组成物。该组成物包括高度无定形的生物相容性聚合物和一种药物物质，该药物物质与一种亲水疏水性材料形成疏水离子复合物。还提供了一种压缩反溶剂法制造该组成物的方法，各种包含该组成物的产品形式和该组成物的各种用途。
• Compositions for spore removal
  申请人：3M INNOVATIVE PROPERTIES COMPANY

  公开号：US10555889B2

  公开（公告）日：2020-02-11

  Disclosed herein are compositions that include at least about 85 wt % of a hydroalcoholic solution that includes at least about 1 wt % water; and about 30 to about 85 wt % of at least one C1 to C4 alkyl alcohol based on the total weight of the hydroalcoholic solution; and acrylate copolymer particles dispersed in the hydroalcoholic solution, the acrylate copolymers particles being the reaction product of a reaction mixture, the reaction mixture including monomers, the monomers including from about 5 wt % to about 50 wt % of at least one high Tg monomer; and from about 20 w % to about 80 wt % of at least one low Tg monomer where the wt % of the low and high Tg monomers are with respect to the total weight of the monomers in the reaction mixture, wherein the particles have a number average diameter of at least about 100 nm.

  本文公开的组合物包括至少约85重量％的水醇溶液，其中包括至少约1重量％的水；以及基于水醇溶液总重量的约30至约85重量％的至少一种C1至C4烷基醇；和分散在水醇溶液中的丙烯酸酯共聚物颗粒，丙烯酸酯共聚物颗粒是反应混合物的反应产物，反应混合物包括单体，单体包括约5重量％至约50重量％的至少一种高Tg单体；和约 20 w % 至约 80 w % 的至少一种低 Tg 单体，其中低 Tg 和高 Tg 单体的重量占反应混合物中单体的总重量，颗粒的平均直径至少为约 100 nm。
• SUSTAINED-RELEASE COMPOSITION INCLUDING AMORPHOUS POLYMER
  申请人：University Technology Corporation

  公开号：EP1073419A2

  公开（公告）日：2001-02-07